Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, with a portfolio centered on orthobiologics and spinal implant systems. The XTNT news feed on Stock Titan aggregates company-issued updates and regulatory disclosures so readers can follow how Xtant communicates its strategy, product launches, and financial performance.
Recent news releases describe Xtant’s emphasis on its core biologics business and regenerative medicine capabilities. The company has announced the commercial launch of products such as CollagenX™, a bovine collagen particulate product for surgical wound closure, and OsteoFactor Pro™, a growth factor-based biologic designed to improve bone healing across orthopedic and spine procedures. Xtant has also introduced Trivium™, a next-generation demineralized bone matrix allograft, and nanOss Strata™, a synthetic bone graft manufactured from hydroxycarbonapatite and designed to mimic human bone structure and support osteoconductivity and cellular activity.
Company news also covers strategic transactions and portfolio changes. Xtant has reported entering into, and subsequently completing, the sale of certain non-core Coflex and CoFix spinal implant assets and its Paradigm Spine GmbH international hardware business to Companion Spine entities, describing these divestitures as a way to sharpen its focus on biologics and strengthen its balance sheet.
Investors and analysts following XTNT news will find quarterly earnings announcements, including revenue trends, gross margin, net income, adjusted EBITDA, and cash flow metrics, as well as financial guidance for the year. The company also issues notices about participation in investor conferences, annual meeting details, and governance developments such as changes to its Board of Directors and amendments to equity incentive plans.
By reviewing the XTNT news stream, readers can see how Xtant presents its mission of honoring the gift of donation, its product development priorities in orthobiologics and wound closure, and the financial and strategic milestones it reports through press releases and SEC-related communications.
Xtant Medical Holdings (XTNT) has announced a rights offering of up to $15 million in common stock, with a record date set for November 5, 2020. Each stockholder will receive subscription rights enabling them to purchase shares at a price of $1.07 per share. The offering begins on November 5, 2020, pending registration approval, and concludes on December 4, 2020, with over-subscription privileges available. The company intends to distribute subscription materials by November 6, 2020. This offering aims to bolster Xtant's funding for developing surgical solutions for spinal disorders.
Xtant Medical Holdings (XTNT) is set to release its third quarter financial results for the period ending September 30, 2020, on October 29, 2020, before market open. A conference call featuring CEO Sean Browne and CFO Greg Jensen will take place on the same day at 9 AM ET to discuss the results. The call can be accessed via dial-in or webcast. Xtant Medical specializes in surgical solutions for spinal disorders, with a focus on orthobiologics and spinal implant systems.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has regained compliance with NYSE American listing standards, specifically maintaining stockholders' equity of at least $6 million after facing losses. This compliance was achieved through a debt restructuring transaction, involving the issuance of approximately 57.8 million shares at $1.07 each, in exchange for $40.8 million in loans and $21.1 million in PIK Interest. The compliance marker will be removed, positively impacting XTNT's standing on the NYSE American.
Xtant Medical Holdings (NYSE American: XTNT) announced the completion of a debt restructuring aimed at enhancing its capital structure. This restructuring reduces its total indebtedness to under $16 million and lowers its cost of debt. Approximately 57.8 million shares were issued to lenders, converting about $40.8 million in loans into equity at an exchange price of $1.07 per share. Following the restructuring, OrbiMed funds own approximately 94.5% of XTNT's stock. Additionally, Xtant plans a rights offering for existing shareholders to purchase stock at the same price.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced a Restructuring and Exchange Agreement aimed at improving its capital structure. This agreement involves converting approximately $40.8 million in loans into about 57.8 million shares of common stock at an exchange price of $1.07 per share. Post-restructuring, Xtant will have less than $17 million in debt. The agreement also includes launching a rights offering for stockholders to purchase common stock valued at $15 million. The restructuring aims to facilitate future investments and compliance with NYSE American listing standards.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for Q2 2020 after market close on August 3, 2020. The results will be discussed in a conference call hosted by CEO Sean Browne and CFO Greg Jensen at 4:30 PM ET on the same day. Interested parties can join the call via dial-in or register for a webcast through the company’s website. Xtant focuses on surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implant systems aimed at facilitating spinal fusion.
Summary not available.